Loading
Lemaitre Vascular Inc Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest was filed 28 Mar 2022.
Lemaitre Vascular Inc: what insiders have been doing
This page follows insider dealings at Lemaitre Vascular Inc as filed with SEC (Form 4), a company from the Healthcare & Pharma sector. From 18 October 2025 to 18 October 2026, the disclosure feed for Lemaitre Vascular Inc logged 60 filings by 11 insiders.
There is no open-market purchase to report; the filings show 2 sales worth €13.9M by 2 insiders. LeMaitre George W filed the largest sale, €13.6M, on 2 March 2026.
Between a trade and the moment it shows up on SEC (Form 4), the median delay is 2 days. Section 16 rules allow two business days to file each Form 4. A sale on its own says little: insiders also sell to pay tax, fund a purchase or diversify.
With 60 filings in twelve months, the company is more active than the median of 19 filings across the 5,813 companies we follow on the same exchange. Our records for Lemaitre Vascular Inc go back to 2016, with 2 purchases and 34 sales on the open market in total. The 10-K for the year ended 31 December 2025 shows 249.6 m USD of revenue and 57.7 m USD of net income and a dividend of 0.80 USD per share.
For comparison within the same sector, see the insider buying recorded at Anixa Biosciences Inc and Vivos Inc. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.
Insider Decl.
282
Thresholds
n/a
Buy Volume
€4,272
2 ops. · all time
Sell Volume
€50M
34 ops. · all time
Who traded when
BuySaleGeorge W. LeMaitre3 sales
Lawrence J. Jasinski3 sales
David B. Roberts1 sale
Analyst consensus: bullish or bearish?
Analysts rate Lemaitre Vascular Inc Buy (bullish), based on 7 analysts. Average price target: US$107.00.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 7,812 of 24,158 companies
60.3
score / 100
Value44
Quality76
FCF yld4.0%
Earn yld3.1%
EV/EBITDA22.4x
ROE17%
Gross mgn72%
Net mgn23%
Debt/EBITDA2.0x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
US$80.82
Analyst consensus
7 analystsBuy
US$81.00Target US$107.00(+32%)US$132.00
Income statement
RevenueUS$249.6M
Gross profitUS$178.5M72% margin
EBITDAUS$90.8M36% margin
Net incomeUS$57.7M25.0% margin
Valuation
PER (trailing)28.4x
PER (forward)25.4x
P/Book4.4x
Beta0.47
Balance sheet & cash
Market capUS$1.8B
Total debtUS$185.6M
Free Cash FlowUS$74.5M
Debt / Equity45%
Profitability & ownership
ROE16.8%
ROA7.4%
% insiders6.5%
% institutions104.3%
Last declaration on 3 September 2026
Declarations282 total
3,444 shares@ US$48.600.0089% mcap12.6% of flowCommon StockSEC:0001193125-26-381984:0
4,322 shares@ US$103.9430.028% mcap100.0% of flowCommonSEC144:0001950047-26-007384
2,941 shares@ US$35.480.0047% mcap19.6% of flowCommon StockSEC:0001193125-26-174316:0
2,625 shares@ US$35.488.5% of flowCommon StockSEC:0001193125-26-106295:0
3,311.68 shares@ US$107.675210.4% of flowCommon StockSEC:0001193125-26-106293:0
2 shares0Common StockSEC:0001193125-26-104162:0
150,000 shares@ US$106.755728.2% of flowCommon StockSEC:0001193125-26-086259:0
476 shares0Common StockSEC:0001193125-26-086322:0
476 shares0Common StockSEC:0001193125-26-086315:0
476 shares0Common StockSEC:0001193125-26-086311:0
476 shares0Common StockSEC:0001193125-26-086305:0
476 shares0Common StockSEC:0001193125-26-086299:0
1,893 shares0Common StockSEC:0001193125-26-086296:0
1,051 shares0Common StockSEC:0001193125-26-086289:0
1,514 shares0Common StockSEC:0001193125-26-086276:0
2,672 shares@ US$37.292.9% of flowCommon StockSEC:0001193125-26-041325:0
1,229 shares@ US$37.294.2% of flowCommon StockSEC:0001193125-26-010637:0
54 shares0Common StockSEC:0001193125-25-319553:0
25 shares0Common StockSEC:0001193125-25-319552:0
5 shares0Common StockSEC:0001193125-25-319547:0
5 shares0Common StockSEC:0001193125-25-319545:0
5 shares0Common StockSEC:0001193125-25-319542:0
5 shares0Common StockSEC:0001193125-25-319537:0
11 shares0Common StockSEC:0001193125-25-319550:0
25 shares0Common StockSEC:0001193125-25-319548:0
25 of 282 declarations
About Lemaitre Vascular Inc
LeMaitre Vascular, Inc. (ticker: LMAT) is a U.S.-based medical device company listed on the NASDAQ in the United States and focused on peripheral vascular disease. The company is headquartered in Burlington, Massachusetts. It was founded in 1983 by vascular surgeon George D. LeMaitre, and its long-standing strategy has been to serve a narrowly defined but clinically important market: tools, implants, and services used by vascular surgeons to treat arterial and venous disease, especially complex cases where standard solutions may be less effective.
LeMaitre operates as a specialist rather than a broad-based medtech conglomerate. Its portfolio includes valvulotomes, carotid shunts, embolectomy and occlusion catheters, biologic and cardiac patches, biologic and synthetic vascular and dialysis grafts, anastomotic clips, and radiopaque tape. In practical terms, the company sells products used in vascular surgery, dialysis access, lower-extremity bypass, carotid procedures, and related interventions. This focus gives LeMaitre a differentiated position with surgeons and hospitals that value procedure-specific solutions, clinical performance, and consistent product availability.
Read moreShow less
From a competitive standpoint, LeMaitre benefits from being a niche leader in a highly specialized segment of the medical device market. Its commercial model is built around direct relationships with surgeons and hospital systems, supported by a global distribution footprint. The company describes itself as reaching more than 90 countries, with operations across North America, Europe, and Asia-Pacific. It also maintains regional infrastructure outside the United States, including a European headquarters in Germany and an Asia-Pacific headquarters in Singapore, which supports broader international penetration and local market access.
Recent developments have remained supportive of the company’s growth narrative. LeMaitre has continued to expand through both product innovation and acquisitions. A notable acquisition was Artegraft, which broadened the company’s biologic and dialysis-access offering and strengthened its position in access-related vascular procedures. More recently, 2025 earnings releases showed continued sales growth, with stronger performance in catheters and grafts, alongside improved gross margin and operating leverage. Management also indicated that the international rollout of Artegraft is progressing ahead of plan. For equity investors, LMAT stands out as a focused, profitable niche medtech company with durable exposure to structural demand in vascular care, particularly in the United States and abroad.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
